Perspective Therapeutics EBIT per Share
The EBIT per Share of Perspective Therapeutics (CATX) as of Oct 23, 2026 is -1.54 USD. In the previous year, EBIT per Share was 0.15 USD — a change of -1,138.96% (lower).
Get this data via API
Financial Data API
EBIT per Share
-1.54USD
YoY
-1,138.96%
Last updated:
EBIT per Share of Perspective Therapeutics is 2025 -1.54 USD. EBIT per Share of Perspective Therapeutics was 2024 0.15 USD. It decreases by -1,138.96% lower compared to the previous year.
The Perspective Therapeutics EBIT per Share history
3 Years
10 Years
25 Years
Max
EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-0.28 USD
Jan 1, 2024
0.15 USD
Jan 1, 2025
-1.54 USD
Jan 1, 2026 (e)
-0.98 USD
Jan 1, 2027 (e)
-1.07 USD
Jan 1, 2028 (e)
-0.93 USD
Jan 1, 2029 (e)
-0.68 USD
Jan 1, 2030 (e)
-0.18 USD
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | -0.18USD | -73.02% |
| est | -0.68USD | -27.22% |
| est | -0.93USD | -12.98% |
| est | -1.07USD | +9.68% |
| est | -0.98USD | -36.57% |
| -1.54USD | -1,138.96% | |
| 0.15USD | -153.55% | |
| -0.28USD | +105.41% | |
| -0.13USD | +115.04% | |
| -0.06USD | +22.59% | |
| -0.05USD | -34.84% | |
| -0.08USD | -35.41% | |
| -0.12USD | +5.83% | |
| -0.11USD | +24.10% | |
| -0.09USD | +16.95% | |
| -0.08USD | -5.52% | |
| -0.08USD | -21.03% | |
| -0.11USD | +1.82% | |
| -0.10USD | +0.34% | |
| -0.10USD | -35.20% | |
| -0.16USD | -43.31% | |
| -0.28USD | -26.49% | |
| -0.38USD | -8.73% | |
| -0.42USD | -6.99% | |
| -0.45USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Perspective Therapeutics Stock analysis
What does Perspective Therapeutics do? Perspective Therapeutics Inc is a biotechnology company based in Seattle, United States, specializing in radiopharmaceutical development. The firm employs 163 people and focuses on advanced cancer treatments using proprietary technology that leverages the alpha-emitting isotope 212Pb. This approach delivers targeted radiation to cancer cells via specialized peptides, aiming to maximize efficacy while minimizing toxicity. Additionally, the company develops imaging diagnostics to personalize patient care. Its pipeline includes programs for metastatic melanoma and neuroendocrine tumors, which have entered Phase I/IIa clinical trials at academic institutions. Perspective Therapeutics also produces a 212Pb generator to secure essential isotopes for its clinical activities. The company has been listed on the market since May 31, 2002. Perspective Therapeutics is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Perspective Therapeutics stock
EBIT per Share of Perspective Therapeutics is -1.54 USD in 2025.
EBIT per Share of Perspective Therapeutics changed from 0.15 USD to -1.54 USD, representing a -1,138.96% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Perspective Therapeutics since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Perspective Therapeutics
All Key Metrics — Perspective Therapeutics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth